Otonomy is a biotechnology business based in the US. Otonomy shares (OTIC) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $0.01 – the same closing value as a week prior. Otonomy employs 51 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.01 |
|---|---|
| 52-week range | $0.00 - $0.00 |
| 50-day moving average | $0.11 |
| 200-day moving average | $0.36 |
| Wall St. target price | $9.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.06 |
Historical closes compared with the close of $0.0085 from 2023-04-11
| 1 week (2024-10-06) | N/A |
|---|---|
| 1 month (2024-09-13) | N/A |
| 3 months (2024-07-13) | N/A |
| 6 months (2024-04-13) | N/A |
| 1 year (2023-10-13) | N/A |
|---|---|
| 2 years (2022-10-17) | -92.14% |
| 3 years (2021-10-15) | 1.92 |
| 5 years (2019-10-17) | 2.23 |
| Gross profit TTM | $-245,000 |
|---|---|
| Return on assets TTM | -38.12% |
| Return on equity TTM | -118.86% |
| Profit margin | 0% |
| Book value | $0.38 |
| Market Capitalization | $582,482 |
TTM: trailing 12 months
We're not expecting Otonomy to pay a dividend over the next 12 months.
Over the last 12 months, Otonomy's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Otonomy's is 1.5717. This would suggest that Otonomy's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Otonomy, Inc. , a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.